Literature DB >> 17956954

Quality of life in cured patients with differentiated thyroid carcinoma.

Hendrieke C Hoftijzer1, Karen A Heemstra, Eleonora P M Corssmit, Agatha A van der Klaauw, Johannes A Romijn, Johannes W A Smit.   

Abstract

OBJECTIVE: This study was performed to evaluate the impact of cured differentiated thyroid carcinoma (DTC) on quality of life. Previous studies on quality of life in patients with DTC were hampered by small patient numbers or limited quality-of-life parameters or were uncontrolled.
DESIGN: This was a cross-sectional case-control study.
METHOD: We assessed quality of life in 153 cured DTC patients with a median duration of cure of 6.34 yr (range 0.3-41.8) and studied the contribution of disease-specific, biochemical, and social variables, focusing on the degree of TSH suppression. Four validated health-related questionnaires were used (Short Form-36, Multidimensional Fatigue Index-20, Hospital Anxiety and Depression Scale, and Somatoform Disorder Questionnaire), including multiple aspects of physical, psychological, and social functioning. Patients were compared with 113 controls selected by patients themselves (control group I) and 336 pooled age- and gender-matched controls from other Leiden quality-of-life studies (control group II).
RESULTS: Patients had significantly decreased quality of life in 11 of 16 subscales when compared with control group I. In comparison with control group II, decreased scores in 13 of 16 items were observed. An important independent predictor for quality of life was duration of cure. Quality-of-life parameters were not influenced by serum TSH levels both measured at the time of quality-of-life assessment and measured over time since initial therapy.
CONCLUSIONS: Patients cured for DTC have impaired quality of life, independently of TSH level. Quality-of-life parameters were inversely affected by duration of cure and consequently may be restored after prolonged follow-up.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17956954     DOI: 10.1210/jc.2007-1203

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  43 in total

1.  Worry in Thyroid Cancer Survivors with a Favorable Prognosis.

Authors:  Maria Papaleontiou; David Reyes-Gastelum; Brittany L Gay; Kevin C Ward; Ann S Hamilton; Sarah T Hawley; Megan R Haymart
Journal:  Thyroid       Date:  2019-07-25       Impact factor: 6.568

2.  Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012.

Authors:  Aubrey A Carhill; Danielle R Litofsky; Douglas S Ross; Jacqueline Jonklaas; David S Cooper; James D Brierley; Paul W Ladenson; Kenneth B Ain; Henry G Fein; Bryan R Haugen; James Magner; Monica C Skarulis; David L Steward; Mingxhao Xing; Harry R Maxon; Steven I Sherman
Journal:  J Clin Endocrinol Metab       Date:  2015-07-14       Impact factor: 5.958

3.  A qualitative evaluation of the validity of published health utilities and generic health utility measures for capturing health-related quality of life (HRQL) impact of differentiated thyroid cancer (DTC) at different treatment phases.

Authors:  Katy Gallop; Cicely Kerr; Stacey Simmons; Bryan McIver; Ezra E W Cohen
Journal:  Qual Life Res       Date:  2014-08-09       Impact factor: 4.147

Review 4.  Quality of life in patients with hypoparathyroidism receiving standard treatment: a systematic review.

Authors:  Matthias Büttner; Thomas J Musholt; Susanne Singer
Journal:  Endocrine       Date:  2017-08-18       Impact factor: 3.633

5.  Quality of life is not influenced by the extent of surgery in patients with benign goiter.

Authors:  F Hubertus Schmitz-Winnenthal; Simon Schimmack; Ben Lawrence; Uwe Maier; Miriam Heidmann; Markus W Buchler; Moritz von Frankenberg
Journal:  Langenbecks Arch Surg       Date:  2011-08-02       Impact factor: 3.445

Review 6.  Management of low-risk papillary thyroid carcinoma: unique conventional policy in Japan and our efforts to improve the level of evidence.

Authors:  Iwao Sugitani; Yoshihide Fujimoto
Journal:  Surg Today       Date:  2010-02-24       Impact factor: 2.549

7.  Patient-Reported Quality-of-Life Outcome Measures in the Thyroid Cancer Population.

Authors:  Eve M Roth; Carrie C Lubitz; John Shannon Swan; Benjamin C James
Journal:  Thyroid       Date:  2020-05-14       Impact factor: 6.568

Review 8.  Prognostic utility of BRAF mutation in papillary thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Mol Cell Endocrinol       Date:  2009-10-31       Impact factor: 4.102

9.  Measurement and Variation in Estimation of Quality of Life Effects of Patients Undergoing Treatment for Papillary Thyroid Carcinoma.

Authors:  Carrie C Lubitz; Lucia De Gregorio; Abbey L Fingeret; Konstantinos P Economopoulos; Diana Termezawi; Mursal Hassan; Sareh Parangi; Antonia E Stephen; Elkan F Halpern; Karen Donelan; J Shannon Swan
Journal:  Thyroid       Date:  2016-12-15       Impact factor: 6.568

10.  The impact of thyroid cancer and post-surgical radioactive iodine treatment on the lives of thyroid cancer survivors: a qualitative study.

Authors:  Anna M Sawka; David P Goldstein; James D Brierley; Richard W Tsang; Lorne Rotstein; Shereen Ezzat; Sharon Straus; Susan R George; Susan Abbey; Gary Rodin; Mary Ann O'Brien; Amiram Gafni; Lehana Thabane; Jeannette Goguen; Asima Naeem; Lilian Magalhaes
Journal:  PLoS One       Date:  2009-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.